^
Association details:
| Biomarker: | KIF5B-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report
Published date:
03/22/2021
Excerpt:
...a 70-year-old nonsmoking Chinese man, with rare ALK rearrangement form of, namely, a kinesin family member 5B (KIF5B)-ALK (K20:A20) fusion which was identified in tissue by capture-based NGS. The patient achieved a partial response (PR) after treatment with crizotinib.
DOI:
10.21037/apm-20-2081
